维普中文期刊产品整合服务
14篇 您的检索式:作者名="Pennone"
    题名 作者 年代 出处 被引量
1Comparisons between glucose analogue 2-deoxy-2-(^(18)F)fluoro-D-glucose and ^(18)F-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesions显示文摘AIM: To compare 2-deoxy-2-(^(18)F)fluoro-D-glucose(^(18)FFDG) and ^(18)F-sodium(^(18)F-NaF) positron emission tomography/computed tomography(PET/CT) accuracy in breast cancer patients with clinically/radiologically suspected or known bone metastases.METHODS: A total of 45 consecutive patients with breast cancer and the presence or clinical/biochemical or radiological suspicion of bone metastatic disease underwent ^(18)F-FDG and ^(18)F-fluoride PET/CT. Imaging results were compared with histopathology when available, or clinical and radiological follow-up of at least 1 year. For each technique we calculated: Sensitivity(Se), specificity(Sp), overall accuracy, positive and negative predictive values, error rate, and Youden's index. Mc Nemar's χ~2 test was used to test the difference in sensitivity and specificity between the two diagnostic methods. All analyses were computed on a patient basis, and then on a lesion basis, with consideration ofthe density of independent lesions on the coregistered CT(sclerotic, lytic, mixed, no-lesions) and the divergent site of disease(skull, spine, ribs, extremities, pelvis). The impact of adding ^(18)F-Na F PET/CT to the work-up of patients was also measured in terms of change in their management due to ^(18)F-Na F PET/CT findings. RESULTS: The two imaging methods of ^(18)F-FDG and ^(18)F-fluoride PET/CT were significantly different at the patient-based analysis: Accuracy was 86.7% and 84.4%, respectively(Mc Nemar's χ~2 = 6.23, df = 1, P = 0.01). Overall, 244 bone lesions were detected in our analysis. The overall accuracy of the two methods was significantly different at lesion-based analysis(Mc Nemar's χ~2 = 93.4, df = 1, P < 0.0001). In the lesion density-based and site-based analysis, ^(18)F-FDG PET/CT provided more accurate results in the detection of CT-negative metastasis(P < 0.002) and vertebral localizations(P < 0.002); ^(18)F-Na F PET/CT was more accurate in detecting sclerotic(P < 0.005) and rib lesions(P < 0.04). ^(18)F-Na F PET/CT led to a change of management in 3 of the 45 patients(6.6%) by revealing findings that were not detected at ^(18)F-FDG PET/CT. CONCLUSION: ^(18)F-FDG PET/CT is a reliable imaging tool in the detection of bone metastasis in most cases, with a diagnostic accuracy that is slightly, but significantly, superior to that of ^(18)F-Na F PET/CT in the general population of breast cancer patients. However, the extremely high sensitivity of ^(18)F-fluoride PET/CT can exploit its diagnostic potential in specific clinical settings(i.e., small CT-evident sclerotic lesions, high clinical suspicious of relapse, and negative ^(18)F-FDG PET and conventional imaging).Selene Capitanio Francesca Bongioanni Arnoldo Piccardo Claudio Campus Roberta Gonella Lucia Tixi Mehrdad Naseri Michele Pennone Vania Altrinetti Ambra Buschiazzo Irene Bossert Francesco Fiz Andrea Bruno Andrea DeCensi Gianmario Sambuceti Silvia Morbelli 2016World Journal of Radiology2016,8,2:3
2Role of whole body positron emission tomography/eomputed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site显示文摘Pelosi E Pennone M Deandreis D 2006Q J Nucl Med Mol Imaging2006,50,1:1
3Role of whole body positron emission tomography/computed tomography scan with ^18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site 显示文摘Pelosi E Pennone M Deandreis D 2006Q J Nucl Med Mol Imaging2006,50,1:1
4Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site显示文摘Pelosi E Pennone M Deandreis D 2006QJ Nucl Med Mol Imaging2006,50,1:1
5Role of whole body positron emission tomography/computed tomography scan with ^18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site 显示文摘Pelosi E Pennone M Deandis D 2006Q J Nucl Med Mol huaging2006,50,1:1
6Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site显示文摘Pelosi E Pennone M Deandreis D 2006Q J Nucl Med Mol Imag- ing2006,50,1:1
7Role of whole body positron emission tomography/computed tomography scan with ^18F- fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site 显示文摘Pelosi E Pennone M Deandreis D 2006Q J Nucl Med Mol Imaging2006,50,1:1
8^99 mTc-HMPAO-leukocyte sein- tigraphy in patients with symptomatic total hip or knee arthroplasty: improved diagnostic accuracy by means of semiquantitative evaluation 显示文摘Pelosi E Baiocco C Pennone M 2004J Nucl Med2004,45,:1
9Role of whole body positron emission tomography/computed tomography scan with ^18F- fluorode- oxyglucose in patients with biopsy proven tumor metastases from unknown primary site显示文摘Pelosi E Pennone M Deandreis D 2006Q J Nucl Med Mol Imaging2006,1,:1
10Role of whole body positron emission tomography/computed tomography scan with 《'18》F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site显示文摘Pelosi E Pennone M Deandreis D 2006Q J Nucl Med Mol Imaging2006,50,1:1
11Teenager donation: investi gation of 848 high school students 显示文摘Pierini L Valdez P Pennone P 2009Transplantation Proceed- ings2009,41,8:1
12Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site显示文摘Pelosi E Pennone M Deandreis D 2006Q J Nucl Med Mol Imaging2006,50,1:1
13Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases form unknown primary site显示文摘Pelosi E Pennone M Deandreis D 0,,01:1
14Role of whole body positron emission tomography/computed tomography scan witIl 18F-fluorodeoxyglucose in patients with biopsy proven pumor metastases from unknown primary site显示文摘Pelosi E Pennone M Deandreis D 2006Q J Nucl Med Mol Imaging2006,,:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费